Genetics of the cardiometabolic syndrome: New insights and therapeutic implications

Therapeutic Advances in Cardiovascular Disease

Volumn 1, Issue 1, 2007, Pages 37-47

  Sookoian, Silvia ^a   Pirola, Carlos J ^b  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b INSTITUTO DE INVESTIGACIONES MÉDICAS ALFREDO LANARI   (Argentina)

Author keywords

Cardiometabolic Syndrome; Diabetes; Gene; Genetics; Hypertension; Insulin Resistance; Metabolic Syndrome; Obesity; Variants

Indexed keywords

ACETYLCHOLINESTERASE; ADIPONECTIN; CD36 ANTIGEN; CELL NUCLEUS RECEPTOR; CYTOCHROME P450 3A4; CYTOCHROME P450 3A7; DISCOIDIN; ESTROGEN RECEPTOR ALPHA; HEPATOCYTE NUCLEAR FACTOR 4ALPHA; INSULIN; INSULIN RECEPTOR; LAMIN A; LAMIN C; LEPTIN; LIPID; NITRIC OXIDE SYNTHASE; PENTRAXIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP); PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROPERDIN; PROTEIN BCL 6; PROTEIN SERINE THREONINE KINASE; PYRUVATE CARBOXYLASE; SERINE PROTEINASE INHIBITOR; SEROTONIN TRANSPORTER; UPSTREAM STIMULATORY FACTOR 1;

BIOINFORMATICS; CHROMOSOME 4; COMPUTER PROGRAM; DISEASE MODEL; DRUG TARGETING; DYSLIPIDEMIA; ENVIRONMENTAL FACTOR; FATTY LIVER; FEEDING BEHAVIOR; GENE IDENTIFICATION; GENE LOCUS; GENE MAPPING; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; HYPERTENSION; INFLAMMATION; INHERITANCE; MENTAL STRESS; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OVARY POLYCYSTIC DISEASE; PATHOGENESIS; PHENOTYPE; PHYSICAL ACTIVITY; PRIORITY JOURNAL; QUANTITATIVE TRAIT LOCUS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOSIS; CARDIOVASCULAR DISEASE; GENETICS; GENOMICS;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; GENETIC VARIATION; GENOMICS; HUMANS; METABOLIC SYNDROME X;

EID: 59049085845     PISSN: 17539447     EISSN: None     Source Type: Journal    
DOI: 10.1177/1753944707082702     Document Type: Review

References (88)

1. Adie, E.A. et al. (2006) SUSPECTS: enabling fast and effective prioritization of positional candidates, Bioinformatics 22: 773–774.
2. Aerts, S. et al. (2006) Gene prioritization through genomic data fusion, Nat Biotechnol 24: 537–544.
3. Alberti, K.G. et al. (2005) The metabolic syndrome – a new worldwide definition, Lancet 366: 1059–1062.
4. Alberti, K.G., Zimmet, P.Z. (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation, Diabet Med 15: 539–553.
5. Altshuler, D. et al. (2000) The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes, Nat Genet 26: 76–80.
6. Andersen, G. et al. (2006) Studies of the association of the GNB 3 825C> T polymorphism with components of the metabolic syndrome in white Danes, Diabetologia 49: 75–82.
7. Arya, R. et al. (2002) Factors of insulin resistance syndrome – related phenotypes are linked to genetic locations on chromosomes 6 and 7 in nondiabetic mexican–americans, Diabetes 51: 841–847.
8. Barker, D.J. et al. (1990) Fetal and placental size and risk of hypertension in adult life, Br Med J 301: 259–262.
9. Binder, A. (2007) A review of the genetics of essential hypertension, Curr Opin Cardiol 22: 176–184.
10. Chanock, S.J. et al. (2007) Replicating genotype– phenotype associations, Nature 447: 655–660.
11. Chinetti-Gbaguidi, G. et al. (2005) Role of the PPAR family of nuclear receptors in the regulation of metabolic and cardiovascular homeostasis: new approaches to therapy, Curr Opin Pharmacol 5: 177–183.
12. Connolly, H.M. et al. (1997) Valvular heart disease associated with fenfluramine–phentermine, N Engl J Med 337: 581–588.
13. Costa, L.A. et al. (2002) The ACE insertion / deletion polymorphism is not associated with the metabolic syndrome (WHO Definition) in Brazilian type 2 diabetic patients, Diabetes Care 25: 2365–2366.
14. Cowley, A.W. (2006) The genetic dissection of essential hypertension, Nat Rev Genet 7: 829–840.
15. Despres, J.P. and Lemieux, I. (2006) Abdominal obesity and metabolic syndrome, Nature 444: 881–887.
16. Desvergne, B. and Wahli, W. (1999) Peroxisome proliferator-activated receptors: nuclear control of metabolism, Endocr Rev 20: 649–688.
17. Di, M. et al. (2004) The endocannabinoid system and its therapeutic exploitation, Nat Rev Drug Discov 3: 771–784.
18. Dina, C. et al. (2007) Comment on “A common genetic variant is associated with adult and childhood obesity”, Science 315: 187.
19. Dubern, B. et al. (2001) Mutational analysis of melanocortin-4 receptor, agouti-related protein, and alpha–melanocyte–stimulating hormone genes in severely obese children, J Pediatr 139: 204–209.
20. Erkkila, A.T. et al. (2002) Variation in the fatty acid binding protein 2 gene is not associated with markers of metabolic syndrome in patients with coronary heart disease, Nutr Metab Cardiovasc Dis 12: 53–59.
21. Farooqi, I.S. (2006) Monogenic human obesity syndromes, Prog Brain Res 153: 119–125.
22. Farooqi, I.S. et al. (2003) Clinical Spectrum of Obesity and Mutations in the Melanocortin 4 Receptor Gene, N Engl J Med 348: 1085.
23. Ford, E.S. et al. (2002) Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey, J Am Med Assoc 287: 356–359.
24. Francis, G.A. et al. (2006) Peroxisomal proliferator activated receptor–gamma deficiency in a Canadian kindred with familial partial lipodystrophy type 3 (FPLD3), BMC Med Genet 7: 3.
25. Gemma, C. et al. (2006) Mitochondrial DNA Depletion in Small– and Large–for–Gestational– Age Newborns, Obesity (Silver Spring) 14: 2193–2199.
26. Guettier, J.M. et al. (2005) Polymorphisms in the fatty acid–binding protein 2 and apolipoprotein C-III genes are associated with the metabolic syndrome and dyslipidemia in a South Indian population, J Clin Endocrinol Metab 90: 1705–1711.
27. Hainer, V. et al. (2006) Serotonin and norepinephrine reuptake inhibition and eating behavior, Ann NY Acad Sci 1083: 252–269.
28. Hegele, R.A. (2001) Monogenic dyslipidemias: window on determinants of plasma lipoprotein metabolism, Am J Hum Genet 69: 1161–1177.
29. Hegele, R.A. (2005) Genetic and physiological insights into the metabolic syndrome, Am J Physiol Regul Integr Comp Physiol 289: R663–R669.
30. Hegele, R.A. et al. (2001) Common genomic variation in LMNA modulates indexes of obesity in Inuit, J Clin Endocrinol Metab 86: 2747–2751.
31. Heils, A. et al. (1996) Allelic variation of human serotonin transporter gene expression, J Neurochem 66: 2621–2624.
32. Herbert, A. et al. (2006) A common genetic variant is associated with adult and childhood obesity, Science 312: 279–283.
33. Hotamisligil, G.S. (2003) Inflammatory pathways and insulin action, Int J Obes Relat Metab Disord 27(Suppl 3): S53–S55.
34. Hotamisligil, G.S. (2006) Inflammation and metabolic disorders, Nature 444: 860–867.
35. Kahn, R. (2007) Metabolic syndrome: is it a syndrome? Does it matter? Circulation 115: 1806–1810.
36. Kajantie, E. (2006) Fetal origins of stress-related adult disease, Ann NY Acad Sci 1083: 11–27.
37. Kelley, D.E. et al. (2002) Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes, Diabetes 51: 2944–2950.
38. Kissebah, A.H. et al. (2000) Quantitative trait loci on chromosomes 3 and 17 influence phenotypes of the metabolic syndrome, Proc Natl Acad Sci USA 97: 14478–14483.
39. Kyrou, I. et al. (2006) The endocannabinoid system as a target for the treatment of visceral obesity and metabolic syndrome, Ann NY Acad Sci 1083: 270–305.
40. Langefeld, C.D. et al. (2004) Linkage of the metabolic syndrome to 1q23–q31 in Hispanic families: the Insulin Resistance Atherosclerosis Study Family Study, Diabetes 53: 1170–1174.
41. Lee, H.K. et al. (2005) Mitochondria-based model for fetal origin of adult disease and insulin resistance, Ann NY Acad Sci 1042: 1–18.
42. Lee, Y.J. and Tsai, J.C. (2002) ACE gene insertion / deletion polymorphism associated with 1998 World Health Organization definition of metabolic syndrome in Chinese type 2 diabetic patients, Diabetes Care 25: 1002–1008.
43. Loos, R.J. et al. (2003) Genome-wide linkage scan for the metabolic syndrome in the HERITAGE Family Study, J Clin Endocrinol Metab 88: 5935–5943.
44. Loos, R.J. et al. (2007) Comment on “A common genetic variant is associated with adult and childhood obesity”, Science 315: 187.
45. Lopez-Bigas, N. and Ouzounis, C.A. (2004) Genome-wide identification of genes likely to be involved in human genetic disease, Nucleic Acids Res 32: 3108–3114.
46. Mani, A. et al. (2007) LRP 6 mutation in a family with early coronary disease and metabolic risk factors. Science 315: 126–128.
47. Martin, S., Nicaud, V. et al. (2003) Contribution of APOA 5 gene variants to plasma triglyceride determination and to the response to both fat and glucose tolerance challenges, Biochim Biophys Acta 1637: 217–225.
48. Mein, C.A. et al. (2005) Selection of candidate genes in hypertension, Methods Mol Med 108: 107–129.
49. Meirhaeghe, A. et al. (2005) Lack of association between certain candidate gene polymorphisms and the metabolic syndrome, Mol Genet Metab 86: 293–299.
50. Miller, M. et al. (2007) APOC 3 promoter polymorphisms C-482T and T-455C are associated with the metabolic syndrome, Arch Med Res 38: 444–451.
51. Mootha, V.K. et al. (2003) PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes, Nat Genet 34: 267–273.
52. Muller, T.D. et al. (2007) No evidence for an involvement of variants in the cannabinoid receptor gene (CNR1) in obesity in German children and adolescents, Mol Genet Metab 90: 429–434.
53. Multiple authors (2007) Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls, Nature 447: 661–678.
54. Mutch, D.M. and Clement, K. (2006) Unraveling the genetics of human obesity, PLoS Genet 2: e188.
55. Nathan, D.M. (2007) Rosiglitazone and Cardiotoxicity – Weighing the Evidence, N Engl J Med.
56. Ncep. (2001) Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III), J Am Med Assoc 285: 2486–2497.
57. Neve, B.P. et al. (2000) Role of the peroxisome proliferator-activated receptors (PPAR) in atherosclerosis, Biochem Pharmacol 60: 1245–1250.
58. Nisoli, E. et al. (2007) Defective mitochondrial biogenesis: a hallmark of the high cardiovascular risk in the metabolic syndrome? Circ Res 100: 795–806.
59. Olivieri, O. et al. (2003) Apolipoprotein C-III, metabolic syndrome, and risk of coronary artery disease, J Lipid Res 44: 2374–2381.
60. Pausova, Z. et al. (2000) Role of tumor necrosis factor-alpha gene locus in obesity and obesity-associated hypertension in French Canadians, Hypertension 36: 14–19.
61. Perez-Iratxeta, C. et al. (2002) Association of genes to genetically inherited diseases using data mining, Nat Genet 31: 316–319.
62. Pollex, R.L. et al. (2006) Metabolic syndrome in aboriginal Canadians: prevalence and genetic associations, Atherosclerosis 184: 121–129.
63. Porter, J.R. and Barrett, T.G. (2005) Monogenic syndromes of abnormal glucose homeostasis: clinical review and relevance to the understanding of the pathology of insulin resistance and beta cell failure, J Med Genet 42: 893–902.
64. Pravenec, M. and Kurtz, T.W. (2007) Molecular genetics of experimental hypertension and the metabolic syndrome: from gene pathways to new therapies, Hypertension 49: 941–952.
65. Redon, R. et al. (2006) Global variation in copy number in the human genome, Nature 444: 444–454.
66. Russo, P. et al. (2007) Genetic Variations at the Endocannabinoid Type 1 Receptor Gene (CNR1) Are Associated with Obesity Phenotypes in Men, J Clin Endocrinol Metab 92: 2382–2386.
67. Saxena, R. et al. (2007) Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels, Science 316: 1331–1336.
68. Schoonjans, K. et al. (1996) PPARalpha and PPARgamma activators direct a distinct tissuespecific transcriptional response via a PPRE in the lipoprotein lipase gene, EMBO J 15: 5336–5348.
69. Schupp, M. et al. (2005) Molecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity, Diabetes 54: 3442–3452.
70. Scott, L.J. et al. (2007) A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants, Science 316: 1341–1345.
71. Shih, D.Q. and Stoffel, M. (2002) Molecular etiologies of MODY and other early-onset forms of diabetes, Curr Diab Rep 2: 125–134.
72. Siffert, W. (2005) G protein polymorphisms in hypertension, atherosclerosis, and diabetes, Annu Rev Med 56: 17–28.
73. Smith, A.J. et al. (2007) INSIG 2 gene polymorphism is not associated with obesity in Caucasian, Afro-Caribbean and Indian subjects, Int J Obes (Lond).
74. Sonnenberg, G.E. et al. (2004) A novel pathway to the manifestations of metabolic syndrome, Obes Res 12: 180–186.
75. Sookoian, S. et al. (2005 a) Peroxisome proliferator-activated receptor gamma and its coactivator-1 alpha may be associated with features of the metabolic syndrome in adolescents, J Mol Endocrinol 35: 373–380.
76. Sookoian, S. et al. (2005 b) The G-308A promoter variant of the tumor necrosis factor-alpha gene is associated with hypertension in adolescents harboring the metabolic syndrome, Am J Hypertens 18: 1271–1275.
77. Sookoian, S. et al. (2005 c) Meta-analysis on the G-308A tumor necrosis factor alpha gene variant and phenotypes associated with the metabolic syndrome, Obes Res 13: 2122–2131.
78. Sookoian, S. et al. (2007) Short allele of serotonin transporter gene promoter is a risk factor for obesity in adolescents, Obesity (Silver Spring) 15: 271–276.
79. Stancakova, A. et al. (2006) Effect of gene polymorphisms on lipoprotein levels in patients with dyslipidemia of metabolic syndrome, Physiol Res 55: 483–490.
80. Stoll, M. et al. (2000) New target regions for human hypertension via comparative genomics, Genome Res 10: 473–482.
81. Tenenbaum, A. et al. (2005) Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons, Cardiovasc Diabetol 4: 14.
82. Turek, F.W. et al. (2005) Obesity and metabolic syndrome in circadian Clock mutant mice, Science 308: 1043–1045.
83. van Driel, M.A. et al. (2005) GeneSeeker: extraction and integration of human disease-related information from web-based genetic databases, Nucleic Acids Res 33: W758–W761.
84. Vimaleswaran, K.S. et al. (2006) Thr 54 allele carriers of the Ala54Thr variant of FABP 2 gene have associations with metabolic syndrome and hypertriglyceridemia in urban South Indians, Metabolism 55: 1222–1226.
85. Weiss, R. et al. (2004) Obesity and the metabolic syndrome in children and adolescents, N Engl J Med 350: 2362–2374.
86. Yamamoto, M. et al. (2004) Association of GNB 3 gene with pulse pressure and clustering of risk factors for cardiovascular disease in Japanese, Biochem Biophys Res Commun 316: 744–748.
87. Yumuk, V.D. (2006) Targeting components of the stress system as potential therapies for the metabolic syndrome: the peroxisome proliferator-activated receptors, Ann NY Acad Sci 1083: 306–318.
88. Zeggini, E. et al. (2007) Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes, Science 316: 1336–1341.